The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

LAMAs were found to be safe and effective in the treatment of COPD and have been recommended by international clinical guidelines for the management of symptoms in COPD. A population-based cohort ...

Please provide your email address to receive an email when new articles are posted on . Perioperative combination therapy using a long-acting muscarinic antagonist and long-acting beta agonist may be ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

Researchers found that umeclidinium-vilanterol was associated with a lower risk for a first moderate or severe COPD exacerbation vs glycopyrrolate-formoterol. HealthDay News — Umeclidinium-vilanterol ...

The risk for severe adverse events for patients with chronic obstructive pulmonary disease was significantly lower among those treated with glycopyrronium/indacaterol ...

Triple therapy may improve asthma symptoms, particularly among patients requiring systemic corticosteroids to treat severe exacerbations, a study finds. Adding long-acting muscarinic antagonists ...

The rate of new chronic obstructive pulmonary disease (COPD) cases decreased from 2001 to 2020, although the prevalence of COPD has increased.

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

April 14, 2020--Clinicians grappling with the pharmacologic management of COPD in patients complaining of exercise intolerance or dyspnea now have new guidance. The American Thoracic Society has ...